These were typically temporary and disappeared as the body acclimated
It's a white crystalline powder that generally appears as fine crystalline grains or a fine form
The Clinical Case: Do GLP-1 Drugs Deliver Value
While BPC-157 does not contain a disulfide bond vulnerable to reduction the way some peptides do, acidic co-administration solutions can accelerate peptide hydrolysis
Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
